Comparison of efficacy and safety of Vilazodone,Escitalopram and Amitriptyline in patients of depressio

Phase 4

• Conditions: Health Condition 1: null- MAJOR DEPRESSIVE DISORDER

• Registration Number: CTRI/2017/10/010284
• Lead Sponsor: Dr Renuka Kadam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Closed to Recruitment of Participants
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

i)Newly diagnosed patients of major depressive disorder (as per Diagnostic and Statistical Manual of Mental Disorder, edition V)

ii)Hamilton Depression Rating Score(HAMD-17) >= 22

iii)Aged between 18-60 years

iv)Either gender

Exclusion Criteria

i)Pregnant and lactating women

ii)Women of reproductive age group who are not practicing a reliable method of contraception

iii)Patients of severe depression who may not respond to pharmacotherapy alone in the opinion of the psychiatrist

iv)Treatment with electroconvulsive therapy within 3 months

v)Any other psychiatric disorders except generalized anxiety disorder

vi)Abnormal renal/hepatic function

vii)Patients requiring other psychotropic medications, central nervous system active drugs

viii)Patients on drug therapy for any other systemic disorder

ix)Patients who have taken an investigational drug or participated in an investigational drug trial within the past 30 days

Study & Design

• Study Type: Interventional
• Study Design: Not specified